Answers are grounded in this paper and cite their sources.
Compared with atorvastatin, rosuvastatin was associated with increased risk of hematuria, proteinuria, and KFRT. Among patients with eGFR <30 ml/min per 1.73 m², 44% were prescribed a rosuvastatin daily dose exceeding the FDA's recommended 10 mg daily dose. Our findings suggest the need for greater care in prescribing and monitoring rosuvastatin, particularly in patients who receive high doses or who have severe CKD.
No takes yet. Share an insight, caveat, or question.
Shin et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: